AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00610428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Staccato Prochlorperazine 10 mg
Description: Inhaled Prochlorperazine10 mg
Study NCT02908607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal imaging
Description: Examination of the cervix by thermal imaging camera
Study NCT02284152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: infant-led feeding
Description: mothers' feeding practices and infant intakes were compared between a typical feeding condition and an infant-led feeding condition, where the experimenter ensured the feeding was in response to infant hunger and fullness cues.
Study NCT01266759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NuvaRing
Description: For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
Study NCT01266759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethisterone Acetate tablets - 5mg
Description: Norethisterone Acetate tablets 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment
Study NCT01692470 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: Patients will be taking rilpivirine hydrochloride as per the dosing regimen given on product insert approved in Philippines (ie, 1 tablet of 25 mg orally once a day) in combination with anti-retroviral (ARV) medications.
Study NCT04117958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 199
Description: AMG 199 is a BiTE® molecule designed to direct T cells towards MUC17-expressing cells.
Study NCT02937285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta 1a
Description: Subcutaneous injection of 44µg 3 times a week
Study NCT02937285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta 1a
Description: Subcutaneous injection of 44µg 3 times a week
Study NCT02937285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 10 mg / m² monthly infusion for 6 months
Study NCT02599610 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital vaginal examination
Description: Patients will be subject to digital vaginal examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
Study NCT02599610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transperineal ultrasound examination
Description: Patients will be subject to transperineal ultrasound examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
Study NCT00391118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Study NCT00391118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00391118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Study NCT00391118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00391118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Study NCT00391118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02606864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (BAYa2502)
Description: Oral Intake of 4 x 30 mg nifurtimox tablets
Study NCT02034500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. sonnei 1790GAHB
Study NCT03617679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rucaparib
Description: Participants allocated to the active ingredient arm will receive Rucaparib twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Medication should be taken around the same time every day, with 8 or more ounces of water.
Study NCT03617679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Participants allocated to the placebo arm will receive a placebo tablet (that looks identical to the active ingredient tablet) twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Tablet should be taken around the same time every day, with 8 or more ounces of water.
Study NCT00580905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: IV infusion of adenosine at a dose of 80 mcg/kg/min for 30 minutes.
Study NCT00580905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitroprusside
Description: To compare the effects of adenosine on increasing cytokines, sodium nitroprusside will be infused at 5 mcg/kg/min (a dose expected to produce similar systemic effects to adenosine)
Study NCT00580905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.~A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion.
Study NCT02486406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/ritonavir
Description: Film-coated tablet for oral use
Study NCT02486406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir
Description: Film-coated tablet for oral use
Study NCT02486406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Film-coated tablet for oral use
Study NCT02486406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir mini tablet
Description: Film-coated tablet for oral use
Study NCT02486406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paritaprevir mini tablet
Description: Film-coated tablet for oral use
Study NCT02486406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir mini tablet
Description: Film-coated tablet for oral use
Study NCT02486406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir mini tablet
Description: Film-coated tablet for oral use
Study NCT02486406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin solution
Description: Oral solution
Study NCT03158558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerated, Multi-Couple Group CBCT for PTSD
Description: Intensive weekend retreat version of cognitive-behavioral conjoint therapy for PTSD (Monson \& Fredman, 2012)
Study NCT02322697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous administration of L-carnitine
Description: Chronic intravenous administration of L-carnitine (1000mg on each dialysis session) for 1 year in hemodialysis patients
Study NCT02034500 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04770194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-8008 Prototype Capsule A
Description: Oral
Study NCT04770194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-8008 Prototype Capsule B
Description: Oral
Study NCT04770194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study NCT02470962 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observation by serial echocardiography with extended techniques and cardiac magnetic resonance imaging
Study NCT04837274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose (480 mg)
Study NCT04837274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active
Description: Tary Cherry (480 mg)
Study NCT00550355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0360324
Description: 3 doses of PD 0360324 (Dose level 1) administered over 12 weeks
Study NCT00550355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0360324
Description: 3 doses of PD 0360324 (Dose level 2) administered over 12 weeks
Study NCT01744730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Schedule includes 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day will be allowed for children receiving clindamycin as part of clinical care.
Study NCT04489888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV infusion given on Day 1 of each 21-day cycle
Study NCT04489888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 mg/mL/minute IV infusion given on Day 1 of each 21-day cycle
Study NCT04489888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: At investigator's choice, paclitaxel 100 mg/m\^2 IV infusion given on Day 1 and Day 8 of each 21-day cycle or paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each 21-day cycle
Study NCT01975389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bococizumab (PF-04950615)
Description: 150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
Study NCT01975389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
Study NCT03550963 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: rice-richen meal
Description: Participants in group one will be provided with rice-richen meal. All participants will be required to test and record blood glucose.
Study NCT03550963 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: wheaten-richen meal
Description: Participants in group two will be provided with wheaten-richen meal.All participants will be required to test and record blood glucose.
Study NCT00874744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 1.25mg bevacizumab (0.05ml)
Study NCT00874744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Description: 4.0 mg Triamcinolone acetonide injection
Study NCT01485952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196 (Low Dose)
Description: 10 mg once daily administration (immediate release capsule)
Study NCT01485952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196 (High Dose)
Description: 100 mg once daily administration (immediate release capsule)
Study NCT01485952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily administration (immediate release capsule)
Study NCT00078390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-3304
Description: S-3304 will be administered at the tolerable dose BID along with chemo-irradiation
Study NCT00078390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chemo-irradiation
Description: Standard of care chemo-irradiation
Study NCT00078390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemo-irradiation
Description: Standard of care chemo-irradiation
Study NCT04300400 — intervention group
Intervention type: OTHER
Intervention: Delphi questionnaire
Description: Statements on OAB topics, rated along their level of appropriateness on a scale from 1 to 9. Multiple rounds are organised to reach consensus on a topic.
Study NCT04983147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-training follow-up
Description: After 7 weeks of training to women were completed, women were included in the follow-up program.For 6 mounts. This application will only be made in the experimental group.It will be made by phone call.~This follow-up will increase motivation and answer questions regarding obesity management.~It was made by calling every 15 days.
Study NCT04331392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spatial Navigation Intervention
Description: The 16-week intervention is completed daily, 5 days/week, remotely from home on a designated study website. Each week participants learn a new city through navigation tasks which increase in difficulty day-to-day and have a total of 4 levels of difficulty, with the goal of being able to independently navigate the city by the end of the week via Google Street View. Participants complete end-of-day multiple-choice tasks, testing what they learned with 3 types of allocentric questions: 1) predicting the next street/landmark, 2) distance judgement and 3) vector mapping. Participants also complete a map placement task, which involves reporting the locations of all studied landmarks/streets.~Participants are presented with auditory rewards in the forms of short audio clips about landmarks, written encouragement in the form pop-ups (e.g., Good work, keep it up!), and coffee card rewards based on adherence to the intervention (e.g.,$5 bi-weekly if 100% of intervention is completed).
Study NCT04331392 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Videos
Description: The 16-week active control, remote video intervention is completed daily, 5 days a week by participants on a designated website. Participants placed in the active control group are trained on educational topics by watching videos of Ted Talks, to control for the effects of generalized environmental enrichment of the same dose as targeted navigation training. For each day of training, participants are asked to select between an option of 2 possible videos, watching a total of three videos per day. To ensure compliance and sufficient attention to the videos, at the end of each video, participants are asked to rate 5 aspects of the content (relevance, interest, comprehensibility, complexity, informative), and speaker (persuasiveness, quality of delivery, facial expression, convincingness, captivation), on a scale of 1 (lowest) to 5 (highest). Additionally, as with remote navigation participants, they are given written and monetary rewards.
Study NCT00550355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0360324
Description: 3 doses of PD 0360324 (Dose level 3) administered over 12 weeks
Study NCT00550355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 doses of Placebo administered over 12 weeks
Study NCT04464174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib administered orally (400 mg) once a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle
Study NCT04464174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine administered orally (1000 mg/m2) twice a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle
Study NCT03784612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-technology for healthy eating habits
Description: Access to smartphone-app, including a 12 week healthy eating program. A new theme on healthy dietary habits is presented each week.
Study NCT01909752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.
Study NCT01909752 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DRibble vaccine
Description: DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43.
Study NCT01909752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4). Immediately following vaccination and for four days following each vaccine cycle (total 5 days) imiquimod will be applied to a 4 x 5-cm outlined area of healthy extremity skin that includes the vaccine site.
Study NCT01909752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. A volume of 0.2 cc will be delivered by the CADD-MSTM 3 Ambulatory infusion pump at a rate of 0.008 cc/hr. The pump will be refilled after three days for a total of six days of infusion.
Study NCT01909752 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Description: Immunization with HPV vaccine will consist of two 0.5-mL intramuscular injection at the time of the first and third vaccinations. The preferred site of administration is the deltoid region of the upper arm.
Study NCT01860690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 50 mg / meter squer Intramuscular (IM) MTX.
Study NCT04464174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin 1.23 mg/m2 administered intravenously Days 1 and 8 of every 21-day cycle
Study NCT04464174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC5 administered intravenously day 1 of every 21-day cycle
Study NCT04464174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered intravenously (1000 mg/m2) at days 1 and 8 of every 21-day cycle
Study NCT04086056 — intervention group
Intervention type: OTHER
Intervention: NIRS monitoring
Description: Regional cerebral oxygen saturation (rScO₂) will be collected by NIRS monitoring before anesthesia induction, during surgery and after extubation, in children with craniosynostosis.
Study NCT01999920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: 10mg to 40mg per day for 12 weeks
Study NCT01999920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One to two pills per day for 12 weeks
Study NCT04731805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moving On After Breast Cancer
Description: Patient education intervention that is evidence-based, physical therapy, patient \& family centered through the use of face to face instruction, a booklet, and therapeutic exercise DVD. The education materials are designed to deliver information on short term, long term, and late physical and functional effects of breast cancer treatment and given to breast cancer survivors before beginning cancer treatment. The education materials are designed to be used before, during, and after breast cancer treatment.
Study NCT03067727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: The DVI contains 10 mg Dinoprostone
Study NCT03067727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product is identical with the active product except that it does not contain Dinoprostone.
Study NCT02894021 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classic closure
Description: mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
Study NCT02894021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: padding
Description: areas of padding and running sutures between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h
Study NCT03809845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-density surface electromyography
Description: High-density surface electromyography
Study NCT00930358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEOPA
Description: anaesthetic gaz inhalation
Study NCT00930358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: general anaesthesia
Description: Anaesthetic intravenous route
Study NCT03221257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone (PFD)
Description: Participants will receive PFD titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
Study NCT03221257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Plac)
Description: Participants will receive a Plac, matched to resemble PFD, titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
Study NCT03221257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: Participants will receive MMF titrated up to a target dose of 1500 mg taken twice daily as tolerated (4-step titration occurring at monthly intervals).
Study NCT03221257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate Mofetil (MMF)
Description: Participants will receive MMF titrated up to a target dose of 1500 mg taken twice daily as tolerated (4-step titration occurring at monthly intervals).
Study NCT00122148 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Feedback on provision of care